[144] Nektar Therapeutics SEC Filing

Rhea-AI Filing Summary

Nektar Therapeutics (NKTR) filed a Form 144 notice for a proposed sale of 1,721 common shares held by Jonathan Zalevsky. The shares are to be sold through Fidelity Brokerage Services on the NASDAQ with an aggregate market value reported as $57,688.44 and the company outstanding share count shown as 19,018,573. The approximate sale date is 09/04/2025. The shares were acquired via restricted stock vesting on four dates in 2023–2024 (totaling 1,721 shares). The filing also discloses two prior sales in the past three months: 725 shares on 08/19/2025 for $19,277.83 and 485 shares on 09/02/2025 for $14,600.10. The filer attests there is no undisclosed material information.

Positive

• Clear regulatory compliance: The Form 144 discloses acquisition dates, vesting origins, broker, and aggregate value.
• Transparency on past sales: Prior disposals on 08/19/2025 and 09/02/2025 are reported with amounts and gross proceeds.

Negative

• Insider selling activity: The filer has recently sold shares (725 and 485 shares) and is proposing additional sales, which some investors may view negatively.

Insights

Securities Analyst

TL;DR: Routine insider sale notice showing small insider disposals totaling 1,721 shares; not clearly material to valuation.

The Form 144 documents a proposed sale of 1,721 common shares through Fidelity with an aggregate market value of $57,688.44 and prior recent disposals of 725 and 485 shares. The shares originated from restricted stock vesting across four dates in 2023–2024, indicating these are compensation-related holdings being liquidated. The absolute dollar amounts disclosed are modest relative to typical market caps for publicly traded issuers, suggesting limited direct market impact. Disclosure is consistent with regulatory requirements for reporting intended insider sales.

Corporate Governance Expert

TL;DR: The filing reflects compliance with Rule 144 and includes the standard insider attestation; governance implications are limited.

The notice provides required transaction detail, vesting history, and the seller's attestation regarding material nonpublic information. The pattern—restricted stock vested over time then sold—aligns with standard executive compensation practice and Rule 144 reporting. From a governance perspective, timely and complete reporting supports transparency; there is no information here of trading under a 10b5-1 plan or other instructions disclosed in the filing.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	1721	57688.44	19018573	09/04/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	11/15/2023	Restricted Stock Vesting	Issuer			138	11/15/2023	Compensation
Common	02/15/2024	Restricted Stock Vesting	Issuer			443	02/15/2024	Compensation
Common	05/15/2024	Restricted Stock Vesting	Issuer			554	05/15/2024	Compensation
Common	08/15/2024	Restricted Stock Vesting	Issuer			586	08/15/2024	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Jonathan Zalevsky 455 Mission Bay Boulevard South San Francisco CA 94158	Common	08/19/2025	725	19277.83
Jonathan Zalevsky 455 Mission Bay Boulevard South San Francisco CA 94158	Common	09/02/2025	485	14600.10

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the NKTR Form 144 disclose about the proposed sale?

The filing reports a proposed sale of 1,721 common shares through Fidelity with an aggregate market value of $57,688.44, approximate sale date 09/04/2025, on NASDAQ.

Who is the filer named in the Form 144 for NKTR?

The seller is identified as Jonathan Zalevsky with an address in San Francisco, CA, listed on the filing.

How were the shares being sold acquired?

All 1,721 shares were acquired via restricted stock vesting on four dates: 11/15/2023 (138), 02/15/2024 (443), 05/15/2024 (554), and 08/15/2024 (586).

Were there any sales of NKTR shares by the filer in the past three months?

Yes. The filing lists sales of 725 shares on 08/19/2025 for $19,277.83 and 485 shares on 09/02/2025 for $14,600.10.

What does the filer represent about material information?

By signing, the filer represents they do not know any material nonpublic information about the issuer that has not been publicly disclosed.

Which broker is handling the proposed sale?

The broker listed is Fidelity Brokerage Services LLC, address 900 Salem Street, Smithfield, RI.